|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: H2AFY |
Gene summary for H2AFY |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | H2AFY | Gene ID | 9555 |
| Gene name | macroH2A.1 histone | |
| Gene Alias | H2A.y | |
| Cytomap | 5q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | O75367 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9555 | H2AFY | GSM4909281 | Human | Breast | IDC | 9.46e-04 | 2.85e-01 | 0.21 |
| 9555 | H2AFY | GSM4909282 | Human | Breast | IDC | 4.06e-19 | 5.15e-01 | -0.0288 |
| 9555 | H2AFY | GSM4909285 | Human | Breast | IDC | 7.90e-07 | 3.26e-01 | 0.21 |
| 9555 | H2AFY | GSM4909291 | Human | Breast | IDC | 4.01e-04 | 3.58e-01 | 0.1753 |
| 9555 | H2AFY | GSM4909293 | Human | Breast | IDC | 5.10e-15 | 4.19e-01 | 0.1581 |
| 9555 | H2AFY | GSM4909294 | Human | Breast | IDC | 3.31e-09 | 1.99e-01 | 0.2022 |
| 9555 | H2AFY | GSM4909296 | Human | Breast | IDC | 7.71e-08 | -5.18e-02 | 0.1524 |
| 9555 | H2AFY | GSM4909297 | Human | Breast | IDC | 7.46e-14 | 2.76e-02 | 0.1517 |
| 9555 | H2AFY | GSM4909298 | Human | Breast | IDC | 2.15e-18 | 5.08e-01 | 0.1551 |
| 9555 | H2AFY | GSM4909306 | Human | Breast | IDC | 1.39e-04 | 3.21e-01 | 0.1564 |
| 9555 | H2AFY | GSM4909307 | Human | Breast | IDC | 1.65e-04 | 2.94e-01 | 0.1569 |
| 9555 | H2AFY | GSM4909308 | Human | Breast | IDC | 4.96e-22 | 6.03e-01 | 0.158 |
| 9555 | H2AFY | GSM4909311 | Human | Breast | IDC | 1.47e-28 | -2.40e-01 | 0.1534 |
| 9555 | H2AFY | GSM4909312 | Human | Breast | IDC | 5.78e-16 | 7.84e-02 | 0.1552 |
| 9555 | H2AFY | GSM4909317 | Human | Breast | IDC | 1.75e-11 | 4.83e-01 | 0.1355 |
| 9555 | H2AFY | GSM4909319 | Human | Breast | IDC | 2.05e-37 | -8.57e-02 | 0.1563 |
| 9555 | H2AFY | GSM4909320 | Human | Breast | IDC | 2.51e-03 | -2.72e-01 | 0.1575 |
| 9555 | H2AFY | GSM4909321 | Human | Breast | IDC | 7.94e-22 | 2.75e-01 | 0.1559 |
| 9555 | H2AFY | brca1 | Human | Breast | Precancer | 5.52e-10 | 4.09e-01 | -0.0338 |
| 9555 | H2AFY | brca2 | Human | Breast | Precancer | 1.82e-13 | 3.71e-01 | -0.024 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| H2AFY | SNV | Missense_Mutation | novel | c.334N>A | p.Glu112Lys | p.E112K | O75367 | protein_coding | deleterious(0.04) | possibly_damaging(0.806) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| H2AFY | insertion | In_Frame_Ins | novel | c.478-1_478insCCCTTGGGGTCACCTTCTCCCTCTTTTCCCCAC | p.Lys159_Lys160insProLeuGlySerProSerProSerPheProHis | p.K159_K160insPLGSPSPSFPH | O75367 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| H2AFY | SNV | Missense_Mutation | novel | c.506C>T | p.Ala169Val | p.A169V | O75367 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| H2AFY | SNV | Missense_Mutation | novel | c.932N>G | p.Phe311Cys | p.F311C | O75367 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| H2AFY | SNV | Missense_Mutation | c.1098N>C | p.Met366Ile | p.M366I | O75367 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-AG-3893-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR | |
| H2AFY | SNV | Missense_Mutation | novel | c.99G>T | p.Lys33Asn | p.K33N | O75367 | protein_coding | deleterious(0) | possibly_damaging(0.867) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| H2AFY | deletion | Frame_Shift_Del | c.288delA | p.Gly97GlufsTer4 | p.G97Efs*4 | O75367 | protein_coding | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| H2AFY | deletion | Frame_Shift_Del | c.78delN | p.Arg27GlyfsTer30 | p.R27Gfs*30 | O75367 | protein_coding | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |||
| H2AFY | deletion | Frame_Shift_Del | c.395delC | p.Pro132GlnfsTer66 | p.P132Qfs*66 | O75367 | protein_coding | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
| H2AFY | SNV | Missense_Mutation | novel | c.79C>T | p.Arg27Trp | p.R27W | O75367 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |